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A B S T R A C T
The prevalence of non-communicable diseases is increasing worldwide, which coincides with the
persistence of infectious diseases including tuberculosis. These can synergistically affect individual and
population health. Three non-communicable diseases that are relevant because of their associated
morbidity, mortality and disability are type 2 diabetes mellitus, chronic kidney disease and rheumatoid
arthritis. There is some evidence that patients with these conditions are at increased risk of acquiring
latent tuberculosis infection (LTBI) and of this progressing to active disease. Unfortunately, evidence on
accurate testing and effective prophylactic treatment in these populations is lacking. This review
discusses current evidence and recommendations for management of LTBI in these patients.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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In recent decades tuberculosis (TB), like many other infectious
diseases, has remained prevalent in many countries around the
world (WHO, 2018a). This collides with the burden of non-
communicable diseases which, although lower or equal to that of
infectious diseases in many regions, is rapidly increasing (Magee
et al., 2018). This scenario can jeopardize the goal of TB elimination,
of which latent tuberculosis infection (LTBI) control is a
fundamental step (WHO, 2014).
The mechanisms behind the development of LTBI are poorly
understood: i.e. why some individuals who are exposed to
Mycobacterium tuberculosis develop LTBI whereas others appear
to eliminate the infection and do not exhibit an immune response
when tested. This makes it even more challenging to evaluate LTBI
in speciﬁc populations such as people living with non-* Corresponding author at: Instituto de Medicina Tropical Alexander von
Humboldt, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430
SMP, Lima 15102, Peru.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).communicable diseases. However, some data indicate that the
risk of developing LTBI upon exposure to the pathogen is greater in
these populations.
In addition, there is growing evidence suggesting that the risk of
individuals with LTBI developing active TB is greater in some non-
communicable diseases which affect the function of the immune
system, namely diabetes mellitus type 2 (DM-2), chronic kidney
disease (CKD) and rheumatoid arthritis (RA). To effectively manage
this increased risk, data are required to improve the diagnosis,
treatment and prevention of LTBI and active TB in patients with
these diseases.
Diabetes mellitus type 2
One of the most relevant non-communicable diseases, DM-2,
has increased in prevalence in low and middle income countries in
recent years. There is evidence of an association between LTBI and
DM-2 (Lee et al., 2017). Initial data suggest that there is a large
heterogeneity in the prevalence of LTBI among DM-2 patients in
different populations, e.g., Indonesia (38.6%) (Koesoemadinata
et al., 2017) or Mexico (51.3%) (Martinez-Aguilar et al., 2015).
However, most of the studies that evaluated LTBI prevalenceiety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
S30 C. Ugarte-Gil et al. / International Journal of Infectious Diseases 80 (2019) S29–S31among DM-2 patients did not compare this against LTBI prevalence
in the general population, leaving room to more accurately
quantify the excess of LTBI in DM-2 patients. This association
between LTBI and DM-2 has implications on global TB control: a
mathematical model forecast that it would not be possible to
eliminate TB by the year 2035 if the incidence of DM-2 continues to
increase worldwide (Pan et al., 2015). There is also evidence of a
relationship between glucose control and the risk of LTBI, whereby
an elevated glucose level (fasting blood glucose or HbA1c) is
associated with an increased risk of developing LTBI (Martinez
et al., 2017). What is not understood is the role of transient
hyperglycemia in LTBI: in patients with active TB an association
between transient hyperglycaemia and mortality and treatment
failure has been demonstrated (Boillat-Blanco et al., 2016), but this
has not been evaluated in populations with LTBI.
An accurate estimation of the prevalence of a disease relies on
strong diagnostic methods. However, the diagnosis of LTBI is
notoriously challenging. Moreover, the methods used to diagnose
LTBI may be less effective in DM-2 patients: these methods are
surrogate tests that infer the presence of LTBI based on the
patient’s immunological response to a stimulus, yet immune
responses may be impaired in people with DM-2, thereby affecting
the performance of these tests. The Tuberculosis Skin Test (TST) has
been shown to have poorer sensitivity, and the Interferon-g release
assays (IGRAs) to have higher rates of false negatives, in patients
with DM-2 than in non-diabetic patients (Faurholt-Jepsen et al.,
2014).
In addition to the increased risk of LTBI in people with DM-2,
these individuals have a higher risk (approximately 3-fold) of
developing active TB (Jeon and Murray, 2008). DM-2 compromises
an individual’s immune system in such a way that favors TB
reactivation. For example, adipocytokines (cytokines produced by
adipose tissue) are associated with inﬂammatory processes in DM-
2, where deregulation of adipocytokines may be related to the
increased risk of TB among patients with DM-2 (Pavan Kumar et al.,
2016).
There are no strong recommendations on whether or not to
offer TB prophylaxis to people diagnosed with DM-2. Unlike other
high-risk populations (e.g., HIV infected patients), LTBI prophylaxis
and treatment in DM-2 have not been thoroughly evaluated; to the
best of our knowledge, no speciﬁc trials have been performed to
determine the effect of any therapy (e.g., isoniazid monotherapy or
rifapentine plus isoniazid) on the risk of developing active TB in
DM-2 patients. Further studies are also needed to investigate the
“antibiotic” properties of DM-2 treatment and control. For
example, there is some evidence that metformin, an oral drug
used for glycaemic control, reduces the growth of M. tuberculosis in
vitro (Singhal et al., 2014), and that achieving good glucose control
may have a role in reducing the risk of patients with LTBI going on
to develop active TB (Lee et al., 2016).
Chronic kidney disease
Patients with renal failure, speciﬁcally patients with chronic
kidney disease (CKD) on dialysis, have a morbidity and mortality
due to infections of about 50% and 20%, respectively. This is likely to
be associated with alterations in the immune system due to uremia
(Romanowski et al., 2016): changes in innate and adaptive immune
responses occur in patients with CKD stage 3, worsening as the
stage progresses, and in patients who are on immunosuppressive
therapy following renal transplantation, which can lead to a state
of uremic inﬂammation (Carrero and Stenvinkel, 2010).
The risk of acquiring LTBI or of developing active TB is high in
patients with CKD because, apart from the immunity problems
already described, comorbidities such as diabetes are common and
these further increase this risk. Incidence of TB increases furtherwith advancing stage of CKD: a study that included more than
8000 patients with CKD in the United Kingdom found an incidence
of 126 cases of active TB per 100,000 patient-years (95% CI 97–169),
and the incidence was lower in those patients with stage 1 CKD (92
per 100,000 patient-years) compared with those who received
dialysis (257 per 100,000 patient-years) (Moran et al., 2018).
Outcomes, including risk of death, are also worse among patients
with TB who are on dialysis. Because of both the increased risk of
TB and worse outcomes, it has been suggested that patients with
CKD or on dialysis should be classiﬁed as a high risk group in need
of interventions to prevent active TB.
Screening should be considered in all people with CKD Stages 4
or 5, and all those on hemodialysis, due to the deterioration in
immunity with CKD progression leading to increasing risk of TB
reactivation, and in all patients awaiting renal transplantation due
to the immunosuppressive therapy required following this
procedure. This should be performed using IGRA or TST, depending
on the availability of the test. The TST is associated with rates of
cutaneous anergy of 50% in CKD patients due to poor immune
responses (Myall and Milburn, 2017). The effect of CKD on IGRA
results is not known, however a recent cost-effectiveness analysis
has shown IGRA to be both more cost-effective and associated with
better outcomes than testing strategies employing TST in patients
with CKD (Campbell et al., 2019). The WHO currently recommends
either TST or IGRA for LTBI screening for these patients (WHO,
2018b).
Rheumatoid arthritis
The introduction of disease-modifying antirheumatic drugs
(DMARDs) such as antitumor necrosis factor (anti-TNF) agents,
which are effective for the management of RA and other
inﬂammatory disorders, has been associated with TB reactivation
in these patients (Cantini et al., 2017). RA patients using DMARDs
have been shown to have a 4-fold increased risk of developing
active TB in comparison to RA patients not receiving DMARDs, and
this risk is increased to 17-fold compared to the general population
(Ai et al., 2015). This is sufﬁcient for all RA guidelines to include
mandatory screening for LTBI and active TB in RA patients in whom
DMARD therapy is being considered (WHO, 2018b; Singh et al.,
2016). However, these guidelines do not recommend screening for
LTBI in RA patients upon diagnosis, despite the evidence of an
elevated risk in these patients compared to those without RA.
Unfortunately, as is the case for other non-communicable
diseases (including DM-2 and CKD), there are no data guiding how
to test for LTBI in RA patients speciﬁcally. One study reported that
the agreement level between TST and IGRA was around 73% in RA
patients (Pyo et al., 2018). As in DM-2 and CKD, the WHO and other
academic institutions including the American College of Rheuma-
tology recommend screening all RA patients for LTBI with either of
these tests (WHO, 2018b; Singh et al., 2016).
No consensus been reached regarding prophylaxis for TB in RA
patients. This is particularly relevant because of the risk of
potential adverse events (i.e. hepatotoxicity) resulting from the use
of isoniazid as a TB preventive therapy, and concerns about its
safety in RA patients who are chronic consumers of several drugs
such as methotrexate, NSAIDs, corticosteroids and other anti-
inﬂammatory agents which have adverse effects of their own.
Conclusions
The world population is facing a shifting of health problems.
This is due to a combination of factors, such as a longer life
expectancy and better healthcare including the development of
new treatments and improved access to healthcare (i.e., universal
health coverage). Nevertheless, in many regions of the world
C. Ugarte-Gil et al. / International Journal of Infectious Diseases 80 (2019) S29–S31 S31infectious diseases such as TB are still highly prevalent. The control
and elimination of these infections depend to a large extent on how
they are managed among high-risk individuals. There is increasing
evidence that people with non-communicable diseases constitute
a high-risk group for both acquiring LTBI and developing active TB.
Although there are clear pathophysiological and immunological
pathways between several non-communicable diseases and LTBI
and/or TB, further studies evaluating better screening tools for
LTBI, safe prophylaxis, and treatments for TB are much needed in
patients with DM-2, CKD and RA.
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